Sector Gamma As
Sector Gamma As reported 40 holdings worth US$461M as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 12, 2026
Sector Gamma As reported 40 holdings worth US$461M as of Jun 30, 2026. Largest: Bristol-myers Squibb Company, Merck & Company, Inc. and Pfizer, Inc. Filed Aug 12, 2026 (Form 13F).
- Holdings
- 40
- Value as reported
- US$461M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Bristol-myers Squibb Company | 726K | US$41.8M | 9.1% |
| Merck & Company, Inc. | 217K | US$27.9M | 6.0% |
| Pfizer, Inc. | 1M | US$24.2M | 5.2% |
| Incyte Corporation | 171K | US$19.4M | 4.2% |
| Elevance Health, Inc. | 44,499 | US$17.2M | 3.7% |
| Biomarin Pharmaceutical Inc. | 295K | US$16.9M | 3.7% |
| Thermo Fisher Scientific Inc | 33,584 | US$16.8M | 3.7% |
| Cvs Health Corporation | 155K | US$16.1M | 3.5% |
| Iqvia Holdings, Inc. | 77,944 | US$15.1M | 3.3% |
| Ionis Pharmaceuticals, Inc. | 189K | US$15M | 3.3% |
| Becton, Dickinson And Company | 93,168 | US$14.1M | 3.1% |
| Abbott Laboratories | 147K | US$13.4M | 2.9% |
| Ge Healthcare Technologies Inc. | 208K | US$13.3M | 2.9% |
| Zimmer Biomet Holdings, Inc. | 142K | US$12.3M | 2.7% |
| Biogen Inc. | 54,163 | US$11.7M | 2.5% |
| Centene Corporation | 162K | US$10.4M | 2.3% |
| Regeneron Pharmaceuticals, Inc. | 15,780 | US$9.84M | 2.1% |
| Bio-rad Laboratories, Inc. | 33,350 | US$9.79M | 2.1% |
| Cardinal Health, Inc. | 40,689 | US$9.67M | 2.1% |
| Amgen Inc. | 26,281 | US$9.52M | 2.1% |
| Bruker Corporation | 152K | US$9.17M | 2.0% |
| Avantor, Inc. | 906K | US$8.97M | 1.9% |
| Ptc Therapeutics, Inc. | 100K | US$8.16M | 1.8% |
| Labcorp Holdings Inc. | 26,019 | US$7.29M | 1.6% |
| Dexcom, Inc. | 102K | US$6.88M | 1.5% |
| Edwards Lifesciences Corporation | 60,402 | US$5.46M | 1.2% |
| Syndax Pharmaceuticals, Inc. | 242K | US$5.28M | 1.1% |
| Boston Scientific Corporation | 121K | US$5.17M | 1.1% |
| Kura Oncology, Inc. | 433K | US$4.75M | 1.0% |
| Travere Therapeutics, Inc. | 80,000 | US$4.54M | 0.99% |
| Crinetics Pharmaceuticals, Inc. | 115K | US$4.29M | 0.93% |
| Tandem Diabetes Care, Inc. | 267K | US$4.03M | 0.87% |
| Iovance Biotherapeutics, Inc. | 968K | US$4.03M | 0.87% |
| Cytokinetics, Incorporated | 45,000 | US$3.83M | 0.83% |
| Organon & Co. | 271K | US$3.67M | 0.80% |
| Ardelyx, Inc. | 687K | US$3.5M | 0.76% |
| Intellia Therapeutics, Inc. | 185K | US$3.13M | 0.68% |
| Arrowhead Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Ascendis Pharma A/s | 0 | US$0 | 0.00% |
| Bridgebio Pharma, Inc. | 0 | US$0 | 0.00% |
| Cogent Biosciences, Inc. | 0 | US$0 | 0.00% |
| Denali Therapeutics Inc. | 0 | US$0 | 0.00% |
| Gilead Sciences, Inc. | 0 | US$0 | 0.00% |
| Humana Inc. | 0 | US$0 | 0.00% |
| Lantheus Holdings, Inc. | 0 | US$0 | 0.00% |
| Unitedhealth Group Incorporated | 0 | US$0 | 0.00% |
Source
View original at SEC
Related